Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.
Mantle Cell Lymphoma
DRUG: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
Overall response, Lugano classification, within 28 days after the last cycle of treatment
Complete response, Lugano classification, within 28 days after the last cycle of treatment|Overall survival, Interval from registration to death from any cause, 5 years|Progression-free survival, Interval from registration to progression or death from any cause, 5 years
Quality of life, EORTC QLQ-C30, within 28 days after the last cycle of treatment|Toxicity, NCI CTCAE version 4.03, within 28 days after the last cycle of treatment
The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.